Fatigue in cancer patients and survivors: Mechanisms and treatment

Primary Psychiatry

Volumn 12, Issue 5, 2005, Pages 53-57

  Bower, Julienne E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; PAROXETINE; PSYCHOSTIMULANT AGENT; TUMOR NECROSIS FACTOR ALPHA;

BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHRONIC INFLAMMATION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; EXERCISE; FATIGUE; HUMAN; IMMUNOTHERAPY; MOOD DISORDER; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE;

EID: 19644391729     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Ries LAG, Eisner MP, Kosary CL, et al, eds. Surveillance, Epidemiology, and End Results Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
2. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004;91(5):822-828.
3. Irvine DM, Vincent L, Graydon JE, Bubela N. Fatigue in women with breast cancer receiving radiation therapy. Cancer Nurs. 1998;21(2):127-135.
4. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998;7(4):301-310.
5. Vogelzang NJ, Breitbart W, Cella D, et al, for the Fatigue Coalition. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997;34(3 suppl 2):4-12.
6. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743-753.
7. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin's disease survivors more fatigued than the general population. J Clin Oncol. 1999;17(1):253-261.
8. Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH, Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16(5):1689-1696.
9. Poulson MJ. Not just tired. J Clin Oncol. 2003;21(suppl 9):112-113.
10. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Huntingt). 1998;12(11A):369-377.
11. Glaus A. Fatigue in patients with cancer. Analysis and assessment. Recent Results Cancer Res. 1998;145:1-172.
12. Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med. 1998;21(1):1-18.
13. Mast ME. Correlates of fatigue in survivors of breast cancer. Cancer Nurs. 1998;21(2):136-142.
14. Jacobsen PB, Stein K. Is fatigue a long-term side effect of breast cancer treatment? Cancer Control. 1999;6(3):256-263.
15. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol. 2002;13(6):965-973.
16. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15(6):979-986.
17. Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):691-698.
18. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528-538.
19. Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma, J Clin Oncol. 2002;20(5):1319-1328.
20. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933:222-234.
21. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987;107(3):293-300.
22. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 1998;83(5):1573-1579.
23. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):445-452.
24. Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage. 1993;8(4):196-200.
25. Mills PJ, Aadler KA, Perez CJ, et al. Soluble ICAM-1 and fatigue in breast cancer patients in response to chemotherapy. Abstract presented at: Annual Scientific Meeting of the American Psychosomatic Society; March 5-8, 2003; Phoenix, AZ.
26. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604-611.
27. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst. 2003;95(15):1165-1168.
28. McEwen BS, Biron CA, Brunson KW, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev. 1997;23(1-2):79-133.
29. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci. 1998;840:684-697.
30. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneur oendocrinology. 2005;30(1):92-100.
31. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med. 2005;67(2):277-280.
32. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry. 2003;8(4):229-240.
33. Massie MJ, Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;(32):57-71.
34. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer. 1998;6(2):101-108.
35. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252-1257.
36. Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S. Fatigue associated with cancer and its treatment. Support Care Cancer. 2002;10(5):389-398.
37. Morrow GR, Hickok JT, Roscoe JA, et al, for the University of Rochester Cancer Center Community Clinical Oncology Program. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21(24):4635-4641.
38. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
39. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;25(1 suppl 1):39-47.
40. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions, Neuropsychopharmacology. 2002;26(5):643-652.
41. Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr. 2004;(32):112-118.
42. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes, J Clin Oncol. 2003;21(9):1660-1668.
43. Helgeson VS, Cohen S, Schulz R, Yasko J. Education and peer discussion group interventions and adjustment to breast cancer. Arch Gen Psychiatry. 1999;56(4):340-347.
44. Helgeson VS, Cohen S, Schulz R, Yasko J. Longterm effects of educational and peer discussion group interventions on adjustment to breast cancer. Health Psychol. 2001;20(5):387-392.
45. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry. 1990;47(8):720-725.
46. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study, Arch Gen Psychiatry. 1981;38(5):527-533.
47. Given B, Given CW, McCorkle R, et al. Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum. 2002;29(6):949-956.
48. Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol. 2002;20(12):2851-2862.
49. Sarhill N, Walsh D, Nelson KA, Homsi J, LeGrand S, Davis MP. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care. 2001;18(3):187-192.
50. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003;21(23):4439-4443.